NCT05348811 2026-01-06
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Phase 2 Completed
Clinical Trials
3 trialsNCT05262959 2024-08-13
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT02870569 2019-03-01
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Completed